Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes | Zendy

Hertzel C. Gerstein | Zendy; Naveed Sattar | Zendy; Julio Rosenstock | Zendy; Chinthanie Ramasundarahettige | Zendy; Richard E. Pratley | Zendy; Renato D. Lópes | Zendy; Carolyn S.P. Lam | Zendy; Nardev S. Khurmi | Zendy; Laura Heenan | Zendy; Stefano Del Prato | Zendy; Leanne Dyal | Zendy; Kelley R. Branch | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes

Author(s) -

Hertzel C. Gerstein,

Naveed Sattar,

Julio Rosenstock,

Chinthanie Ramasundarahettige,

Richard E. Pratley,

Renato D. Lópes,

Carolyn S.P. Lam,

Nardev S. Khurmi,

Laura Heenan,

Stefano Del Prato,

Leanne Dyal,

Kelley R. Branch

Publication year - 2021

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2108269

Subject(s) - type 2 diabetes , medicine , glucagon like peptide 1 receptor , diabetes mellitus , adverse effect , agonist , endocrinology , receptor , glucagon like peptide 1

Four glucagon-like peptide-1 (GLP-1) receptor agonists that are structurally similar to human GLP-1 have been shown to reduce the risk of adverse cardiovascular events among persons with type 2 diabetes. The effect of an exendin-based GLP-1 receptor agonist, efpeglenatide, on cardiovascular and renal outcomes in patients with type 2 diabetes who are also at high risk for adverse cardiovascular events is uncertain.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research